Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral tofacitinib for vitiligo: real-world efficacy and safety
ChiCTR2400092326Phase 4Not yet recruiting
- Sponsor
- Hangzhou Third People's Hospital
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tofacitinib in Vitiligo, sponsored by Hangzhou Third People's Hospital. Primary endpoint: Vitiligo area scoring index. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
03
Conditions
Vitiligo
Beyond the preview
Go deeper on ChiCTR2400092326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092326.